Vaccines against hepatitis B virus
AssigneeAltimmune UK Limited
InventorsBertrand Victor Gilbert Georges, Carlton Bradley Brown
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.
Claims18
A sterile, dried pharmaceutical composition comprising a combination of two or more fluorocarbon-linked peptide constructs, wherein each construct comprises an immunogenic hepatitis B virus peptide sequence covalently attached to a vector for intracellular delivery of the peptide, wherein the vector comprises a chain comprising from 3 to 30 carbon atoms, at least one of which is substituted with fluorine, chlorine, bromine or iodine, and wherein the peptide is from 15 to 60 amino acids in length comprising at least 15 contiguous amino acids shown in any one of SEQ ID NOs:
- 1 to 4 or SEQ ID No:
- 55 or of a sequence having at least 90% identity to one of the sequences shown in SEQ ID NOs:
- 1 to 4 or SEQ ID NO:
- 55 wherein each peptide comprises at least one CD8+ T-cell epitope and at least one CD4+ T-cell epitope and wherein the peptide binds two or more HLA class 1 alleles;
- and wherein the mixture is in a solid form.
A sterile, dried pharmaceutical composition comprising a combination of peptides comprising a sequence shown in each of SEQ ID NOs:
- 24, 25, 28, 34, 33, 36, 37, 38 and 222, wherein each peptide is attached to a fluorocarbon chain having the structure CmFn—CyHx(Sp)-R, where m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3-30, where Sp is an optional spacer moiety and R is the peptide;
- and wherein the mixture is in a solid form.
Dependencies are inferred from the claim text.